149 related articles for article (PubMed ID: 14689108)
1. Angiotensin II antagonists in the treatment of hypertension-effective and efficient?
Müller-Nordhorn J; Willich SN
Herz; 2003 Dec; 28(8):733-7. PubMed ID: 14689108
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
5. New and emerging drug treatments for hypertension.
Krum H; Pellizzer AM
Aust Fam Physician; 1998 Apr; 27(4):235-7, 240-2. PubMed ID: 9581329
[TBL] [Abstract][Full Text] [Related]
6. [Hypertension 2007-2008].
Chatzikyrkou C; Menne J; Haller H
Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
[TBL] [Abstract][Full Text] [Related]
7. Valsartan: new preparation. Just a second-line antihypertensive drug.
Prescrire Int; 1998 Oct; 7(37):144-5. PubMed ID: 10915419
[TBL] [Abstract][Full Text] [Related]
8. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
9. [Cerebrovascular sequelae of hypertension].
Schrader J; Lüders S; Diener HC
Herz; 2003 Dec; 28(8):707-16. PubMed ID: 14689105
[TBL] [Abstract][Full Text] [Related]
10. Redefining efficacy of antihypertensive therapies beyond blood pressure reduction--the role of angiotensin II antagonists.
Conlin PR
Int J Clin Pract; 2005 Feb; 59(2):214-24. PubMed ID: 15854200
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
12. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
de Boer RA; van Veldhuisen DJ; Gans RO; Gansevoort RT
Ned Tijdschr Geneeskd; 2003 Jan; 147(3):96-9. PubMed ID: 12577767
[TBL] [Abstract][Full Text] [Related]
14. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
15. [Angiotensin II antagonists versus ACE inhibitors in the treatment of raised blood pressure].
Andersen RS; Christensen S
Ugeskr Laeger; 2001 Dec; 163(50):7036-9. PubMed ID: 11794033
[TBL] [Abstract][Full Text] [Related]
16. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
Lam S; Choy M
Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of antihypertensive therapy.
Grossman E; Messerli FH
Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
[TBL] [Abstract][Full Text] [Related]
20. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
